Infectious Vaccines Market Size, Share, Trends, Growth Outlook

Infectious Vaccines Market is estimated to increase at a growth rate of 6.7% CAGR over the forecast period from 2024 to 2030.

The Infectious Vaccines Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Type (Inactivated Vaccines, Live Attenuated Vaccines, DNA and Recombinant Vector Vaccines, Others), By Disease(Typhoid, Tuberculosis, Tetanus and Diphtheria, Influenza, Hepatitis, Polio, Others), By Distribution Channel (Hospitals, Retail Pharmacies, Online Distribution).

An Introduction to Infectious Vaccines Market in 2024

The Infectious Vaccines market in 2024 is experiencing significant growth driven by the increasing emphasis on disease prevention, vaccination programs, and global immunization initiatives aimed at controlling the spread of infectious diseases, reducing disease burden, and achieving herd immunity. Vaccines represent one of the most effective public health interventions, offering protection against a wide range of viral, bacterial, and parasitic pathogens responsible for diseases such as influenza, measles, polio, hepatitis, and COVID-19. The market offers a diverse portfolio of infectious vaccines, including live attenuated, inactivated, subunit, conjugate, and recombinant vaccines, designed to stimulate the immune system, induce protective immunity, and prevent infection or disease progression. With factors such as increasing awareness of vaccine-preventable diseases, advancements in vaccine technology, and the emergence of new infectious threats driving demand for innovative vaccine solutions, vaccine manufacturers, research institutions, and global health organizations are investing in vaccine development platforms, adjuvant technologies, and production scale-up capabilities to address evolving public health needs, improve vaccine efficacy, and expand vaccine coverage across diverse populations. Moreover, with a focus on equitable access, vaccine equity, and pandemic preparedness, the market is witnessing efforts to enhance vaccine distribution networks, strengthen cold chain infrastructure, and accelerate vaccine deployment strategies to ensure timely access to safe and effective vaccines for all communities. As the world grapples with the COVID-19 pandemic and other infectious disease challenges, the infectious vaccines market is poised for continued growth and innovation, offering essential tools to protect global health and promote wellbeing for individuals and societies worldwide.

Infectious Vaccines Market Trend: Increasing Focus on Preventive Healthcare and Immunization Initiatives

A notable trend in the Infectious Vaccines market is the growing emphasis on preventive healthcare and immunization initiatives globally. Governments, healthcare organizations, and public health agencies are increasingly prioritizing vaccination programs as a cost-effective means to prevent infectious diseases and reduce their burden on healthcare systems. This trend is driving the demand for a wide range of vaccines, including those targeting viral, bacterial, and other pathogens, to protect individuals and communities against infectious threats.

Market Driver: Expanding Vaccination Coverage and Immunization Campaigns

A significant driver fueling the growth of the Infectious Vaccines market is the expanding vaccination coverage and implementation of immunization campaigns worldwide. With increasing awareness about the importance of vaccines in preventing diseases, coupled with advancements in vaccine development and distribution infrastructure, vaccination rates are on the rise across various demographics and geographies. Government-led initiatives, public-private partnerships, and advocacy efforts are further driving the adoption of vaccines, creating a favorable environment for market expansion.

Infectious Vaccines Market Opportunity: Development of Novel Vaccines for Emerging and Re-emerging Infectious Diseases

An opportunity for the Infectious Vaccines market lies in the development of novel vaccines targeting emerging and re-emerging infectious diseases. The continual evolution of infectious pathogens, along with the potential for outbreaks and pandemics, underscores the need for innovative vaccine solutions to address evolving threats. Pharmaceutical companies and research institutions have the opportunity to leverage advancements in vaccine technologies, such as mRNA vaccines, recombinant vaccines, and viral vector-based vaccines, to develop effective vaccines against emerging infectious agents. By investing in research and development efforts focused on novel vaccine candidates, stakeholders can capitalize on the growing demand for preventive healthcare solutions and contribute to global public health preparedness.

Infectious Vaccines Market Segmentation

By Type
Inactivated Vaccines
Live Attenuated Vaccines
DNA and Recombinant Vector Vaccines
Others
By Disease
Typhoid
Tuberculosis
Tetanus and Diphtheria
Influenza
Hepatitis
Polio
Others
By Distribution Channel
Hospitals
Retail Pharmacies
Online Distribution
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Infectious Vaccines Market Companies

AstraZeneca
BioNTech SE
GSK Plc
Merck & Co. Inc
Moderna Inc
Pfizer Inc
Sanofi
Seqirus
Serum Institute of India Pvt. Ltd
Sinovac

 

 

Reasons to Buy the Infectious Vaccines Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Infectious Vaccines Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Infectious Vaccines Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

 

TABLE OF CONTENTS

1 Introduction to 2024 Infectious Vaccines Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Infectious Vaccines Market Size Outlook, $ Million, 2021 to 2030
3.2 Infectious Vaccines Market Outlook by Type, $ Million, 2021 to 2030
3.3 Infectious Vaccines Market Outlook by Product, $ Million, 2021 to 2030
3.4 Infectious Vaccines Market Outlook by Application, $ Million, 2021 to 2030
3.5 Infectious Vaccines Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Infectious Vaccines Market Industry
4.2 Key Market Trends in Infectious Vaccines Market Industry
4.3 Potential Opportunities in Infectious Vaccines Market Industry
4.4 Key Challenges in Infectious Vaccines Market Industry

5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Infectious Vaccines Market Share by Company (%), 2023
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Infectious Vaccines Market Outlook By Segments
7.1 Infectious Vaccines Market Outlook by Segments
By Type
Inactivated Vaccines
Live Attenuated Vaccines
DNA and Recombinant Vector Vaccines
Others
By Disease
Typhoid
Tuberculosis
Tetanus and Diphtheria
Influenza
Hepatitis
Polio
Others
By Distribution Channel
Hospitals
Retail Pharmacies
Online Distribution

8 North America Infectious Vaccines Market Analysis And Outlook To 2030
8.1 Introduction to North America Infectious Vaccines Markets in 2024
8.2 North America Infectious Vaccines Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Infectious Vaccines Market size Outlook by Segments, 2021-2030
By Type
Inactivated Vaccines
Live Attenuated Vaccines
DNA and Recombinant Vector Vaccines
Others
By Disease
Typhoid
Tuberculosis
Tetanus and Diphtheria
Influenza
Hepatitis
Polio
Others
By Distribution Channel
Hospitals
Retail Pharmacies
Online Distribution

9 Europe Infectious Vaccines Market Analysis And Outlook To 2030
9.1 Introduction to Europe Infectious Vaccines Markets in 2024
9.2 Europe Infectious Vaccines Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Infectious Vaccines Market Size Outlook By Segments, 2021-2030
By Type
Inactivated Vaccines
Live Attenuated Vaccines
DNA and Recombinant Vector Vaccines
Others
By Disease
Typhoid
Tuberculosis
Tetanus and Diphtheria
Influenza
Hepatitis
Polio
Others
By Distribution Channel
Hospitals
Retail Pharmacies
Online Distribution

10 Asia Pacific Infectious Vaccines Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Infectious Vaccines Markets in 2024
10.2 Asia Pacific Infectious Vaccines Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Infectious Vaccines Market size Outlook by Segments, 2021-2030
By Type
Inactivated Vaccines
Live Attenuated Vaccines
DNA and Recombinant Vector Vaccines
Others
By Disease
Typhoid
Tuberculosis
Tetanus and Diphtheria
Influenza
Hepatitis
Polio
Others
By Distribution Channel
Hospitals
Retail Pharmacies
Online Distribution

11 South America Infectious Vaccines Market Analysis And Outlook To 2030
11.1 Introduction to South America Infectious Vaccines Markets in 2024
11.2 South America Infectious Vaccines Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Infectious Vaccines Market size Outlook by Segments, 2021-2030
By Type
Inactivated Vaccines
Live Attenuated Vaccines
DNA and Recombinant Vector Vaccines
Others
By Disease
Typhoid
Tuberculosis
Tetanus and Diphtheria
Influenza
Hepatitis
Polio
Others
By Distribution Channel
Hospitals
Retail Pharmacies
Online Distribution

12 Middle East And Africa Infectious Vaccines Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Infectious Vaccines Markets in 2024
12.2 Middle East and Africa Infectious Vaccines Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Infectious Vaccines Market size Outlook by Segments, 2021-2030
By Type
Inactivated Vaccines
Live Attenuated Vaccines
DNA and Recombinant Vector Vaccines
Others
By Disease
Typhoid
Tuberculosis
Tetanus and Diphtheria
Influenza
Hepatitis
Polio
Others
By Distribution Channel
Hospitals
Retail Pharmacies
Online Distribution

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AstraZeneca
BioNTech SE
GSK Plc
Merck & Co. Inc
Moderna Inc
Pfizer Inc
Sanofi
Seqirus
Serum Institute of India Pvt. Ltd
Sinovac

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Type
Inactivated Vaccines
Live Attenuated Vaccines
DNA and Recombinant Vector Vaccines
Others
By Disease
Typhoid
Tuberculosis
Tetanus and Diphtheria
Influenza
Hepatitis
Polio
Others
By Distribution Channel
Hospitals
Retail Pharmacies
Online Distribution